Pharmaceutical company Eli Lilly ... it's a once-a-day weight management pill. However, the pharmaceutical firm ran into some trouble two years into developing and testing the drug, finding ...

Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has already been approved in the US, China ... Orexigen's weight-loss therapy ...

Eli Lilly’s new GLP-1 weight loss drug, in pill form, would be more affordable than Ozempic Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step ...

Eli Lilly's oral GLP-1 medicine aced a phase 3 study. It should become a new growth driver for the company. There are other reasons to invest in the pharmaceutical leader. Zepbound's prospects ...

Eli Lilly's experimental oral pill, orforglipron, has shown promising results in Phase 3 trials, effectively lowering weight and blood sugar levels similar to Ozempic in diabetes patients.

The highly anticipated results of the trial conducted by pharmaceutical company Eli Lilly ... one weight-loss drug – Saxenda – is included in the scheme, which caps a family’s monthly ...

Plans to file for global approval by end of year Lilly shares rise 16%, Novo Nordisk shares slip Drug ... Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial 9:14 ...